
Ana Carolina Cardoso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4575219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2022, 67, 5272-5279.	1.1	4
2	Staging Fibrosis in Chronic Viral Hepatitis. Viruses, 2022, 14, 660.	1.5	8
3	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 185-198.	3.7	130
4	Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. Annals of Hepatology, 2021, 22, 100341.	0.6	4
5	Current management of NAFLD/NASH. Liver International, 2021, 41, 89-94.	1.9	14
6	Diabetes influences liver stiffness in chronic hepatitis C patients with and without virological cure: A longitudinal study. Clinics, 2021, 76, e3236.	0.6	2
7	The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. European Journal of Gastroenterology and Hepatology, 2020, 32, 231-238.	0.8	13
8	New drugs for nonâ€alcoholic steatohepatitis. Liver International, 2020, 40, 96-101.	1.9	23
9	Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (<scp>CHC</scp>) infected patients evaluated with controlled attenuation parameter (<scp>CAP</scp>). Journal of Viral Hepatitis, 2018, 25, 1244-1250.	1.0	5
10	Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. Journal of Hepatology, 2010, 52, 652-657.	1.8	300